To address these disparities, future clinical guidelines should emphasize routine MGMT testing for all newly diagnosed GBM patients, highlighting populations that are less likely to undergo molecular testing such as the elderly, those with limited insurance coverage, and communities with lower educational attainment. Here, MGMT is linked to glioblastoma.